Navigation Links
Anaphore Appoints Paul A. Grayson President and CEO
Date:6/20/2011

LA JOLLA, Calif., June 20, 2011 /PRNewswire/ -- Anaphore Inc. today announced the appointment of Paul A. Grayson as president and CEO. A life sciences executive with an extensive track record of success in business development and financial transactions for emerging biopharmaceutical companies, Grayson joins Anaphore as it focuses its efforts on the establishment of collaborations with pharmaceutical companies for the discovery and development of novel Atrimer therapeutics. He replaces Katherine S. Bowdish, Ph.D., a co-founder of Anaphore, who will continue to serve the company as a consultant.

"I am proud of the collective accomplishments of the Anaphore team from inception to date including significantly advancing the core platform technology, programs, and forging a critical partnership," said Kathy Bowdish.  "I am confident of the team's ability to execute under Paul's direction as the company embarks in this next exciting stage in its evolution."

"The addition of Paul reflects Anaphore's movement into its next phase of development," said Russell G. Greig, Ph.D., the company's executive chairman. "His deal-making experience and leadership qualities will bring a new dimension to the company as we increase our efforts to unlock the value of our technology platform. We are grateful to Kathy for her success in building a top-notch scientific team and advancing the technology to this sophisticated stage."

Grayson commented, "I've had the opportunity to evaluate many leadership opportunities in the industry over the past months. Anaphore's Atrimer technology caught my attention and stood out as an innovative approach to tackling diseases that were out of reach because of limitations with today's protein drugs.  I am excited to join the company at its current stage and view this as an opportunity that is destined for success."

Grayson previously served as CEO of Fate Therapeutics, a San Diego-based, privately held
'/>"/>

SOURCE Anaphore
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Innerscope Research(R) Appoints Digital Leader, Andre Marquis, as Senior Vice President of Sales and Marketing
2. ID Analytics Appoints Chief Information Officer
3. ID Analytics Appoints Chief Information Officer
4. Innerscope Research(R) Appoints Digital Leader, Andre Marquis, as Senior Vice President of Sales and Marketing
5. BIO-key(R) Appoints Cecilia Welch as Chief Financial Officer
6. Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative
7. Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer
8. Global Rainmakers Appoints James M. Demitrieus as Chief Operating Officer
9. Hoyos Group Appoints Anthony Antolino as Chief Marketing Officer
10. The Science Coalitions 10 questions for the presidential debate
11. Haag honored with Presidential Early Career Scientists Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... 2015 According to a new ... by Technology (Touch-based & Touchless), Application (Consumer Electronics, Automotive, ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... to reach $23.55 Billion by 2020, at a CAGR ... Browse 83 market data T ables and   ...
(Date:6/1/2015)... -- According to a new market ... (Government, Military & Defense, Healthcare, Banking & Finance, ... (Face Recognition, Fingerprint Recognition, Iris Recognition, Palm Recognition, ... Function (Contact and Non-Contact) & Geography ( ... , APAC, Row) - Global Forecast to 2020", ...
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) ... Recognition Market by Solution, by Software, by Hardware, ... report to their offering. The ... become more efficient and cost effective. This has ... from the commercial sector. The development of 3D ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... called microglia are starting to reveal their secrets thanks to ... recently, most of the glory in brain research went to ... were believed to perform the entirety of the information processing ... cells called glia which together account for about half ...
... beautiful wasp species are added to the rare pompilid genus ... species. The two new species A. prima and ... the rest of the representatives of the genus. Both wasps are ... beautiful black color with metallic shine typical for the family. The ...
... Cell Biology , scientists from the EMBL Australia research ... (ARMI) have revealed new insights into how cells organise ... mammalian embryo, just 8-cells large, the roundish cells do ... would determine whether the embryo survived or failed. They ...
Cached Biology News:Not so dumb 2Not so dumb 3Your first hug: How the early embryo changes shape 2
(Date:6/2/2015)... 2015 /CNW/ - Shell today celebrated the North American launch ... with an exhibit the size of a city block ... for media and the public, and special appearances by ... Gasoline provides the best total engine protection by addressing ... gunk and corrosion. "With the launch of ...
(Date:6/2/2015)... and TORONTO , June 2, 2015 ... APS), a clinical-stage company developing new therapeutics that target ... U.S. Food and Drug Administration (FDA) has granted the ... of acute myeloid leukemia (AML). APTO-253, a first-in-class inducer ... candidate in a Phase Ib clinical trial in patients ...
(Date:6/2/2015)... Global Stem Cells Group subsidiary Adimarket ... biologic products for the regeneration and repair of human organs ... Cells Group’s ambitious expansion plans in Latin America, a commitment ... regenerative medicine and stem cell therapies. , Bioquark ... have the ability to alter the regulatory state of human ...
(Date:6/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6wjpd6/bioburden_testing ) has announced the ... , Test, Application & End User - Forecast to ... bioburden testing market is expected to reach $565.6 Million ... a CAGR of 9.8% from 2014 to 2019 ... market is segmented into consumables and instruments. The consumables ...
Breaking Biology Technology:New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 4Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 2Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 3Aptose Biosciences Granted Orphan Drug Designation by the U.S. FDA for APTO-253 in Acute Myeloid Leukemia 4Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3Bioburden Testing Market 2015 - Global Forecasts to 2019 2
... MILLBROOK, N.Y., Jan. 31 Mr. Donald ... today that the company has recently,obtained from ... that cover certain technologies related to cancer ... were developed jointly,by scientists in the Laboratory ...
... India remain hot, as VCs face more competition from private ... ... Venture capitalists will largely,direct their investments to the greentech and biotech ... for venture,funds, according to a recent survey by the U.S. audit, ...
... N.J., Jan. 31 Schering-Plough,Corporation (NYSE: SGP ... Drug,Administration (FDA) has accepted the Peg-IFN (peginterferon alfa-2b),supplemental ... Priority Review status for the adjuvant treatment of ... to the agency,in the fall of 2007., ...
Cached Biology Technology:Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 2Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 4FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 5FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 6
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Anti-Salmonid Ig (H), Alk Phos, (Clone IPA5F12) (mouse IgG2a)...
Rat monoclonal [HK5.3] to B7 RP1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 23308 SwissProtID: O75144...
Biology Products: